BR112015007503A2 - derivados de oxazolina terapeuticamente ativos - Google Patents
derivados de oxazolina terapeuticamente ativosInfo
- Publication number
- BR112015007503A2 BR112015007503A2 BR112015007503A BR112015007503A BR112015007503A2 BR 112015007503 A2 BR112015007503 A2 BR 112015007503A2 BR 112015007503 A BR112015007503 A BR 112015007503A BR 112015007503 A BR112015007503 A BR 112015007503A BR 112015007503 A2 BR112015007503 A2 BR 112015007503A2
- Authority
- BR
- Brazil
- Prior art keywords
- therapeutically active
- derivatives
- oxazoline derivatives
- active oxazoline
- pyrimidine
- Prior art date
Links
- 125000003504 2-oxazolinyl group Chemical class O1C(=NCC1)* 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical group C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000004985 diamines Chemical class 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- -1 oxazolin-2-yl Chemical group 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- DDWBRNXDKNIQDY-UHFFFAOYSA-N thieno[2,3-d]pyrimidine Chemical group N1=CN=C2SC=CC2=C1 DDWBRNXDKNIQDY-UHFFFAOYSA-N 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
resumo derivados de oxazolina terapeuticamente ativos trata-se de compostos de fórmula (i), isto é, derivados de isotiazol[5,4- d]pirimidina e tieno[2,3-d]pirimidina substituída por diamina monocíclica ou bicíclica substituídos por uma porção química de oxazolin-2-ila opcionalmente substituída que são benéficos no tratamento e/ou prevenção de várias enfermidades humanas, incluindo distúrbios inflamatórios, autoimunes ou oncológicos; doenças virais; e rejeição de transplante de órgão e célula.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1217704.4A GB201217704D0 (en) | 2012-10-03 | 2012-10-03 | Therapeutic agents |
| PCT/EP2013/070600 WO2014053581A1 (en) | 2012-10-03 | 2013-10-02 | Therapeutically active oxazoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015007503A2 true BR112015007503A2 (pt) | 2017-07-04 |
Family
ID=47225621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015007503A BR112015007503A2 (pt) | 2012-10-03 | 2013-10-02 | derivados de oxazolina terapeuticamente ativos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9382263B2 (pt) |
| EP (1) | EP2903990B1 (pt) |
| JP (1) | JP6184501B2 (pt) |
| CN (1) | CN104936962B (pt) |
| BR (1) | BR112015007503A2 (pt) |
| CA (1) | CA2886265A1 (pt) |
| ES (1) | ES2639293T3 (pt) |
| GB (1) | GB201217704D0 (pt) |
| IN (1) | IN2015DN03751A (pt) |
| RU (1) | RU2656209C2 (pt) |
| WO (1) | WO2014053581A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016081732A1 (en) | 2014-11-19 | 2016-05-26 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| AR104020A1 (es) * | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
| GB201517263D0 (en) | 2015-09-30 | 2015-11-11 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven | Therapeutic agents |
| GB201521767D0 (en) | 2015-12-10 | 2016-01-27 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D | Therapeutic agents |
| DK3429591T3 (da) | 2016-03-16 | 2023-06-19 | Kura Oncology Inc | Substituerede thieno[2,3-D]pyrimidin-derivater som inhibitorer af Menin-MLL og fremgangsmåder til anvendelse |
| JP2020514388A (ja) | 2017-03-24 | 2020-05-21 | クラ オンコロジー，インク． | 血液悪性腫瘍およびユーイング肉腫を処置するための方法 |
| WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| US11649251B2 (en) | 2017-09-20 | 2023-05-16 | Kura Oncology, Inc. | Substituted inhibitors of menin-MLL and methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2408396A1 (en) * | 2000-04-17 | 2001-10-25 | Basf Aktiengesellschaft | Herbicidal 3-heterocyclic substituted benzisothiazole and benzisoxazole compounds |
| NZ546044A (en) * | 2003-08-29 | 2009-09-25 | Vernalis Cambridge Ltd | Pyrimidothiophene compounds |
| US20080200475A1 (en) | 2005-03-28 | 2008-08-21 | Pfizer Inc. | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors |
| MX2011002263A (es) * | 2008-09-10 | 2011-05-23 | Kalypsys Inc | Aminopirimidinas como inhibidores de receptores de histamina para el tratamiento de enfermedades. |
| JP5647998B2 (ja) * | 2009-03-13 | 2015-01-07 | カトリーケ ユニバーシテイト ルーヴェン、ケー．ユー． ルーヴェン アール アンド ディー | 免疫抑制剤としてのチアゾロピリミジン調節因子 |
| AU2010289321A1 (en) * | 2009-09-04 | 2012-04-05 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| GB201012889D0 (en) | 2010-08-02 | 2010-09-15 | Univ Leuven Kath | Antiviral activity of novel bicyclic heterocycles |
| GB201015411D0 (en) | 2010-09-15 | 2010-10-27 | Univ Leuven Kath | Anti-cancer activity of novel bicyclic heterocycles |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| GB201119401D0 (en) * | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
-
2012
- 2012-10-03 GB GBGB1217704.4A patent/GB201217704D0/en not_active Ceased
-
2013
- 2013-10-02 CA CA 2886265 patent/CA2886265A1/en not_active Abandoned
- 2013-10-02 IN IN3751DEN2015 patent/IN2015DN03751A/en unknown
- 2013-10-02 BR BR112015007503A patent/BR112015007503A2/pt not_active Application Discontinuation
- 2013-10-02 EP EP13776992.3A patent/EP2903990B1/en active Active
- 2013-10-02 ES ES13776992.3T patent/ES2639293T3/es active Active
- 2013-10-02 RU RU2015116643A patent/RU2656209C2/ru not_active IP Right Cessation
- 2013-10-02 US US14/432,842 patent/US9382263B2/en not_active Expired - Fee Related
- 2013-10-02 WO PCT/EP2013/070600 patent/WO2014053581A1/en active Application Filing
- 2013-10-02 JP JP2015535015A patent/JP6184501B2/ja not_active Expired - Fee Related
- 2013-10-02 CN CN201380061725.5A patent/CN104936962B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014053581A1 (en) | 2014-04-10 |
| US20150274748A1 (en) | 2015-10-01 |
| IN2015DN03751A (pt) | 2015-10-02 |
| RU2656209C2 (ru) | 2018-06-01 |
| US9382263B2 (en) | 2016-07-05 |
| ES2639293T3 (es) | 2017-10-26 |
| CN104936962A (zh) | 2015-09-23 |
| CA2886265A1 (en) | 2014-04-10 |
| RU2015116643A (ru) | 2016-11-27 |
| GB201217704D0 (en) | 2012-11-14 |
| JP6184501B2 (ja) | 2017-08-23 |
| EP2903990A1 (en) | 2015-08-12 |
| EP2903990B1 (en) | 2017-06-14 |
| CN104936962B (zh) | 2017-02-22 |
| JP2015531388A (ja) | 2015-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015007503A2 (pt) | derivados de oxazolina terapeuticamente ativos | |
| BR112015014869A2 (pt) | derivados de pirazolo-pirimidina terapeuticamente ativos | |
| CO6440524A2 (es) | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la quinasa janus. | |
| CL2013003472A1 (es) | Compuestos derivados de halogenoalquil-1,3-oxazinas sustituidas, inhibidores de la bace1 y/o bace2; procedimiento de obtencion; composicion farmaceutica que los comprende; su uso en el tratamiento y/o profilaxis de enfermedades tales como diabetes, alzheimer, als, enfermedades autoinmunes inflamatorias, cancer, entre otras. | |
| CR20130617A (es) | Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias | |
| UY36056A (es) | “compuestos de heteroarilo o arilo bicíclicos fusionados “. | |
| CL2012003427A1 (es) | Compuestos derivados de 5-amino-3,6-dihidro-1h-pirazina-2-ona; y uso en el tratamiento de enfermedades tales como alzheimer, senilidad, demencia, entre otras. | |
| EA202090258A3 (ru) | Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний | |
| BR112015010663A2 (pt) | formas de dosagem de ruxolitinib de liberação sustentada | |
| CR20130432A (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20152033A1 (es) | Heterociclos bicicliclos como inhibidores de fgfr | |
| CL2015003444A1 (es) | Compuestos de 3,4 dihidroisoquinolin-2(1h)-ilo | |
| EA202090662A2 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
| BR112015006029A2 (pt) | compostos aza bicíclicos como agonistas de receptor m1 muscarínicos | |
| GT201400213A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| CL2015002606A1 (es) | Compuesto. | |
| WO2013024291A3 (en) | Therapeutically active fused pyrimidine derivatives | |
| BR112014008865A2 (pt) | imidazo[1,2-c]pirimidinas 5,7-substituídas | |
| BR112016011483A2 (pt) | Derivados de imidazotriazina como moduladores de atividade de tnf | |
| BR112014001665A2 (pt) | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz | |
| EA201891050A1 (ru) | Соединения пирроло-, пиразоло-, имидазопиримидина и пиридина, которые ингибируют mnk1 и mnk2 | |
| BR112017019605A2 (pt) | compostos heterocíclicos úteis como inibidores de tnf | |
| CY1116318T1 (el) | Μακροκυκλικη ενωση και μεθοδοι για την παραγωγη της | |
| BR112016029632A2 (pt) | derivados heteroaromáticos bicíclicos fundidos como inibidores de cinase | |
| TR201901338T4 (tr) | Kinaz İnhibitörleri Olarak Pirazolo-Piridin Türevleri |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |